Stellah Mpagama - Concepedia

Author

Stellah Mpagama

Kilimanjaro Christian Medical Centre ORCID

Also Known As

Hadija Semvua, S Mpagama, S. G. Mpagama, S. Mpagama, S.G. Mpagama, SG Mpagama, Stella G Mpagama, Stella G. Mpagama, Stella George Mpagama, Stella Mpagama

170

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Kilimanjaro Christian Medical Centre University of Virginia Radboud University Nijmegen Radboud University Medical Center National Institute for Medical Research

About

Stellah Mpagama is an author at Kilimanjaro Christian Medical Centre specializing in medicine, tuberculosis, and tuberculosis diagnostics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	245
2	Health Sciences	4	4	185
3	Public Health	2	2	24
4	Clinical Nutrition	1	1	10
5	Epidemiology	1	1	14

Stellah Mpagama

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial Martin J. Boeree, Norbert Heinrich, Rob E. Aarnoutse, The Lancet Infectious Diseases	2016	379
Post-tuberculosis lung health: perspectives from the First International Symposium Brian Allwood, Marieke M. van der Zalm, André F.S. Amaral, The International Journal of Tuberculosis and Lung Disease	2020	241
Clinical standards for the assessment, management and rehabilitation of post-TB lung disease Giovanni Battista Migliori, Florian M. Marx, Nicolino Ambrosino, The International Journal of Tuberculosis and Lung Disease	2021	159
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis Devyani Deshpande, Jotam G. Pasipanodya, Stellah Mpagama, Clinical Infectious Diseases	2018	95
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients Norbert Heinrich, Rodney Dawson, Jeannine du Bois, Journal of Antimicrobial Chemotherapy	2015	91
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis R.E. Aarnoutse, Gibson Kibiki, Klaus Reither, Antimicrobial Agents and Chemotherapy	2017	89
Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis Darwin J. Operario, Alexander F. Koeppel, Stephen Turner, PLoS ONE Molecular BiologyGyra Codon 94Antibiotic ResistanceDrug ResistanceMultidrug-resistant Tuberculosis	2017	76
Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy Mohamed I. M. Ahmed, Nyanda Elias Ntinginya, Gibson Kibiki, Frontiers in Immunology	2018	59
The burden and determinants of post-TB lung disease Stellah Mpagama, Kassim Salim Msaji, Oscar Leonard Kaswaga, The International Journal of Tuberculosis and Lung Disease	2021	59
Clinical standards for the dosing and management of TB drugs Jan‐Willem C. Alffenaar, Sophie L. Stocker, Lina Davies Forsman, The International Journal of Tuberculosis and Lung Disease	2022	58

Page 1